Bacher, Ulrike

[["dc.bibliographiccitation.firstpage","58"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Hung, Rayjean J."],["dc.contributor.author","Carreras, J."],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Hari, Parameswaran N."],["dc.contributor.author","Ku, G. H."],["dc.contributor.author","Ayala, E."],["dc.contributor.author","Chen, A. L."],["dc.contributor.author","Chen, Y-B"],["dc.contributor.author","Cohen, Jonathon B."],["dc.contributor.author","Freytes, Cesar O."],["dc.contributor.author","Gale, Robert Peter"],["dc.contributor.author","Kamble, Rammurti"],["dc.contributor.author","Kharfan-Dabaja, Mohamed A."],["dc.contributor.author","Lazarus, Hillard M."],["dc.contributor.author","Martino, Roberto D."],["dc.contributor.author","Mussetti, Alberto"],["dc.contributor.author","Savani, Bipin N."],["dc.contributor.author","Schouten, H. C."],["dc.contributor.author","Usmani, Saad Z."],["dc.contributor.author","Wiernik, Peter H."],["dc.contributor.author","Wirk, Baldeep Mona"],["dc.contributor.author","Smith, Sonali M."],["dc.contributor.author","Sureda, Anna M."],["dc.contributor.author","Hamadani, Mehdi"],["dc.date.accessioned","2018-11-07T10:21:17Z"],["dc.date.available","2018-11-07T10:21:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P < 0.001), 61% vs 20% (P < 0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR) = 0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR = 3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR = 0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors."],["dc.identifier.doi","10.1038/bmt.2015.223"],["dc.identifier.isi","000368469800009"],["dc.identifier.pmid","26437062"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42057"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1476-5365"],["dc.relation.issn","0268-3369"],["dc.title","Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Holler, Ernst"],["dc.contributor.author","Kobbe, Guido"],["dc.contributor.author","Bornhaeuser, Martin"],["dc.contributor.author","Schwerdtfeger, Rainer"],["dc.contributor.author","Nagler, Amon"],["dc.contributor.author","Bethge, Wolfgang A."],["dc.contributor.author","Stelljes, Matthias"],["dc.contributor.author","Uharek, Luiz"],["dc.contributor.author","Wandt, Hannes"],["dc.contributor.author","van Os, Marleen"],["dc.contributor.author","Burchert, Andreas"],["dc.contributor.author","Corradini, Paolo"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Kaufmann, Martin"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Einsele, Hermann"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Zander, Axel R."],["dc.contributor.author","Heinzelmann, Marion"],["dc.contributor.author","Kvasnicka, Michael"],["dc.contributor.author","Thiele, Juergen"],["dc.contributor.author","Niederwieser, Dietger"],["dc.contributor.author","de Witte, Theo M."],["dc.date.accessioned","2018-11-07T10:52:20Z"],["dc.date.available","2018-11-07T10:52:20Z"],["dc.date.issued","2007"],["dc.format.extent","210A"],["dc.identifier.isi","000251100800684"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49090"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a Multicenter prospective trial of the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT)."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3202"],["dc.bibliographiccitation.issue","25"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","3214"],["dc.bibliographiccitation.volume","127"],["dc.contributor.author","Schieferdecker, Aneta"],["dc.contributor.author","Oberle, Anna"],["dc.contributor.author","Thiele, Benjamin"],["dc.contributor.author","Hofmann, Fabian"],["dc.contributor.author","Goethel, Markus"],["dc.contributor.author","Miethe, Sebastian"],["dc.contributor.author","Hust, Michael"],["dc.contributor.author","Braig, Friederike"],["dc.contributor.author","Voigt, Mareike"],["dc.contributor.author","von Pein, Ute-Marie"],["dc.contributor.author","Koch-Nolte, Friedrich"],["dc.contributor.author","Haag, Friedrich"],["dc.contributor.author","Alawi, Malik"],["dc.contributor.author","Indenbirken, Daniela"],["dc.contributor.author","Grundhoff, Adam"],["dc.contributor.author","Bokemeyer, Carsten"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Binder, Mascha"],["dc.date.accessioned","2018-11-07T10:12:39Z"],["dc.date.available","2018-11-07T10:12:39Z"],["dc.date.issued","2016"],["dc.description.abstract","Multiplemyeloma(MM) is a hematological cancer for which immune-based treatments are currently in development. Many of these rely on the identification of highly disease specific, strongly and stably expressed antigens. Here, we profiled the myeloma B-cell immunome both to explore its predictive role in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and to identify novel immunotherapeutic targets. We used random peptide phage display, reverse immunization, and next-generation sequencing-assisted antibody phage display to establish a highly myeloma-specific epitope fingerprint targeted by B-cell responses of 18 patients in clinical remission. We found that allogeneic HSCT more efficiently allowed production of myeloma-specific antibodies compared with autologous HSCT and that a highly reactive epitope recognition signature correlated with superior response to treatment. Next, we performed myeloma cell surface screenings of phage-displayed patient transplant immunomes. Although some of the screenings yielded clear-cut surface binders, the majority of screenings did not, suggesting that many of the targeted antigens may in fact not be accessible to the B-cell immune system in untreated myeloma cells. This fit well with the identification of heat-shock proteins as a class of antigens that showed overall the broadest reactivity with myeloma patient sera after allogeneic HSCT and that may be significantly translocated to the cell surface upon treatment as a result of immunogenic cell death. Our data reveal a disease-specific epitope signature of MM that is predictive for response to treatment. Mining of transplant immunomes for strong myeloma surface binders may open up avenues for myeloma immunotherapy."],["dc.description.sponsorship","Hubertus Wald-Foundation, Hamburg; [110906]"],["dc.identifier.doi","10.1182/blood-2015-10-676536"],["dc.identifier.isi","000378337700014"],["dc.identifier.pmid","27034429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40279"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","A transplant \"immunome\" screening platform defines a targetable epitope fingerprint of multiple myeloma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","146"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Haematologica"],["dc.bibliographiccitation.lastpage","154"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Mendorf, Alexander"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Langebrake, Claudia"],["dc.contributor.author","Rohde, Holger"],["dc.contributor.author","Ayuk, Francis"],["dc.contributor.author","Regier, Marc"],["dc.contributor.author","Christopeit, Maximilian"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Bacher, Adelbert"],["dc.contributor.author","Wolschke, Christine"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Stübig, Thomas"],["dc.date.accessioned","2018-11-07T10:02:55Z"],["dc.date.available","2018-11-07T10:02:55Z"],["dc.date.issued","2015"],["dc.description.abstract","Toxoplasmosis and infections by other opportunistic agents such as Pneumocystis jirovecii constitute life-threatening risks for patients after allogeneic hematopoietic stem cell transplantation. Trimethoprim/sulfamethoxazole (TMP-SMX) has been well established for post-transplant toxoplasmosis and pneumocystis prophylaxis, but treatment may be limited due to toxicity. We explored atovaquone as an alternative and compared it with TMP-SMX regarding toxicity and efficacy during the first 100 days after transplantation in 155 consecutive adult stem cell recipients. Eight patients with a prior history of TMP-SMX intolerance received atovaquone as first-line prophylaxis. TMP-SMX was used for 141 patients as first-line strategy, but 13 patients (9.2%) were later switched to atovaquone due to TMP-SMX toxicity or gastrointestinal symptoms. No active toxoplasmosis or active P. jirovecii infection developed under continued prophylaxis with either TMP-SMX or atovaquone. However, for reasons of TMP-SMX and/or atovaquone toxicity, 7 patients were unable to tolerate any efficacious toxoplasmosis prophylaxis and therefore obtained inhalative pentamidine as P. jirovecii prophylaxis but no toxoplasmosis prophylaxis. Importantly, 2 of these patients developed severe toxoplasmosis. In summary, atovaquone appears as a valid alternative for at least some post-transplant patients who cannot tolerate TMP-SMX. This should be further confirmed by multicenter trials. (C) 2015 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000380757"],["dc.identifier.isi","000361636000003"],["dc.identifier.pmid","25968483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38332"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9662"],["dc.relation.issn","1421-9662"],["dc.relation.issn","0001-5792"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Hari, Parameswaran N."],["dc.contributor.author","Ahn, Kwang Woo"],["dc.contributor.author","Maloney, David G."],["dc.contributor.author","Smith, S."],["dc.contributor.author","Sureda, Anna M."],["dc.contributor.author","Carreras, J."],["dc.contributor.author","Hamadani, Mehdi"],["dc.date.accessioned","2018-11-07T09:56:09Z"],["dc.date.available","2018-11-07T09:56:09Z"],["dc.date.issued","2015"],["dc.format.extent","13"],["dc.identifier.isi","000361204901027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36905"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.publisher.place","Pavia"],["dc.relation.conference","20th Congress of European-Hematology-Association"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","0390-6078"],["dc.title","REDUCED INTENSITY CONDITIONING (RIC) ALLO TRANSPLANTATION IS ASSOCIATED WITH SUPERIOR LONG-TERM DISEASE CONTROL IN RELAPSED/REFRACTORY GRADE I/II (G-I/II) FOLLICULAR LYMPHOMA"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2091"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Biology of Blood and Marrow Transplantation"],["dc.bibliographiccitation.lastpage","2099"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Hari, Parameswaran N."],["dc.contributor.author","Ahn, Kwang Woo"],["dc.contributor.author","Carreras, Jeanette"],["dc.contributor.author","Bachanova, Veronika"],["dc.contributor.author","Bashey, Asad"],["dc.contributor.author","Cohen, Jonathon B."],["dc.contributor.author","D'Souza, Anita"],["dc.contributor.author","Freytes, Cesar O."],["dc.contributor.author","Gale, Robert Peter"],["dc.contributor.author","Ganguly, Siddhartha"],["dc.contributor.author","Hertzberg, Mark S."],["dc.contributor.author","Holmberg, Leona A."],["dc.contributor.author","Kharfan-Dabaja, Mohamed A."],["dc.contributor.author","Klein, Andreas"],["dc.contributor.author","Ku, Grace H."],["dc.contributor.author","Laport, Ginna G."],["dc.contributor.author","Lazarus, Hillard M."],["dc.contributor.author","Miller, Anne-Marie"],["dc.contributor.author","Mussetti, Alberto"],["dc.contributor.author","Olsson, Richard F."],["dc.contributor.author","Slavin, Shimon"],["dc.contributor.author","Usmani, Saad Z."],["dc.contributor.author","Vij, Ravi"],["dc.contributor.author","Wood, William Allen"],["dc.contributor.author","Maloney, David G."],["dc.contributor.author","Sureda, Anna M."],["dc.contributor.author","Smith, Sonali M."],["dc.contributor.author","Hamadani, Mehdi"],["dc.date.accessioned","2018-11-07T09:48:33Z"],["dc.date.available","2018-11-07T09:48:33Z"],["dc.date.issued","2015"],["dc.description.abstract","This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors. (C) 2015 American Society for Blood and Marrow Transplantation."],["dc.identifier.doi","10.1016/j.bbmt.2015.07.028"],["dc.identifier.isi","000364981700009"],["dc.identifier.pmid","26253007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1523-6536"],["dc.relation.issn","1083-8791"],["dc.title","Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Schaab, R."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Dierks, Sascha"],["dc.contributor.author","Parra, Tallo M."],["dc.contributor.author","Martin, R."],["dc.contributor.author","Germing, U."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Lange, F."],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Doehner, Konstanze"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:13:02Z"],["dc.date.available","2018-11-07T10:13:02Z"],["dc.date.issued","2016"],["dc.format.extent","68"],["dc.identifier.isi","000379484600145"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40358"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.publisher.place","Pavia"],["dc.relation.conference","21st Congress of the European-Hematology-Association"],["dc.relation.eventlocation","Copenhagen, DENMARK"],["dc.relation.issn","0390-6078"],["dc.title","17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Schaab, R."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Dierks, Sascha"],["dc.contributor.author","Parra, Tallo M."],["dc.contributor.author","Martin, R."],["dc.contributor.author","Germing, U."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Lange, F."],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Doehner, Konstanze"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:07:38Z"],["dc.date.available","2018-11-07T10:07:38Z"],["dc.date.issued","2016"],["dc.format.extent","236"],["dc.identifier.isi","000385691300583"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39319"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Interdependency between TP53 mutational status, genetic instability and prognosis in MDS and secondary AML"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Hari, Parameswaran N."],["dc.contributor.author","Ahn, Kwang Woo"],["dc.contributor.author","Maloney, David G."],["dc.contributor.author","Smith, Sonali M."],["dc.contributor.author","Sureda, Anna M."],["dc.contributor.author","Carreras, Jeanette"],["dc.contributor.author","Hamadani, Mehdi"],["dc.date.accessioned","2018-11-07T09:57:05Z"],["dc.date.available","2018-11-07T09:57:05Z"],["dc.date.issued","2015"],["dc.identifier.isi","000358036901545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37091"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S446"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","S447"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Badbaran, Anita"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Christopeit, M."],["dc.contributor.author","Wolschke, Christine"],["dc.contributor.author","Ayuk, F."],["dc.contributor.author","Zander, Axel R."],["dc.contributor.author","Alchalby, Haefaa"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Triviai, Ioanna N."],["dc.contributor.author","Fehse, Boris"],["dc.date.accessioned","2018-11-07T10:17:07Z"],["dc.date.available","2018-11-07T10:17:07Z"],["dc.date.issued","2016"],["dc.identifier.isi","000373357601250"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41171"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.publisher.place","London"],["dc.relation.conference","42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation"],["dc.relation.eventlocation","Valencia, SPAIN"],["dc.relation.issn","1476-5365"],["dc.relation.issn","0268-3369"],["dc.title","Impact of molecular residual disease after allografting in myelofibrosis patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]